Navigation Links
Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
Date:3/13/2009

Preclinical Rationale for Clinical Trial Presented at USCAP Meeting

SOUTH SAN FRANCISCO, Calif., March 13 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the enrollment of the first patient in a Phase 2, multi-center clinical trial of R788 (fostamatinib disodium) in patients with refractory or relapsed peripheral T-cell lymphoma (PTCL). The clinical trial's primary objective is to assess the efficacy of R788, an orally bio-available Syk kinase inhibitor, in patients suffering from this subset of non-Hodgkin's lymphoma that originates in the patient's T-cells. Prior studies have suggested increased expression of Syk at the cellular level in many of these patients with PTCL.

"Since we have seen that R788 shows clinical therapeutic benefit in certain types of B-cell lymphomas and that Syk kinase appears to play an important role in certain PTCLs, we believe that R788 may offer new hope to the 12-15% of non-Hodgkin's lymphoma patients with the T-cell variety," said Elliott Grossbard, M.D., executive vice president and chief medical officer of Rigel.

In general, patients with PTCL have a poorer prognosis and fewer treatment options than B-cell lymphoma patients. The standard treatment regimen for PTCL, known as CHOP, fails to provide adequate or durable responses in many patients. CHOP is a treatment regimen consisting of cyclophosphamide, hydroxydoxorubicin, vincristine (oncovin) and prednisone.

Pre-clinical Results Presented at USCAP Meeting

In a related matter, results of a pre-clinical study of R788 were presented in an oral session of the United States and Canadian Academy of Pathology annual meeting in Boston this week on March 9, 2009. The presentation, entitled, "An Orally Available Syk Tyrosine Kinase Inhibitor Induces Apoptosis
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
2. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
3. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
4. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
5. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
6. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
7. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
8. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
9. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
10. Novexels NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
11. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... -- Sanofi (EURONEXT: SAN and NYSE: SNY ) announced ... , examining the selective JAK2 inhibitor SAR302503 for myelofibrosis ... The primary endpoint assessed the proportion of patients achieving ... in previous trials, the most common adverse events were ... presented at an upcoming medical congress. ...
(Date:5/16/2013)... , May 17, 2013 ... and Switzerland,s Cytos Biotechnology AG today ... a Phase 1 clinical trial with their H1N1 influenza vaccine ... technology. In this first Phase 1 clinical trial, the safety ... to protect against H1N1 influenza infection will be evaluated. ...
(Date:5/16/2013)...  Today, the National Patient Advocate Foundation acknowledges that ... Representatives recently approved a bill that would prohibit insurers ... out-of-pocket fees for newer, more expensive oral anti-cancer drugs ... severe side-effects. However, the bill was amended to include ... to be a barrier to patients with cancer and ...
Breaking Medicine Technology:Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 2National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 3
(Date:5/19/2013)... Utah (PRWEB) May 19, 2013 ... on small business health insurance . Zane ... traditional employer sponsored health benefits, is the leader ... and health reimbursement arrangements . , According ... and the self-employed intrinsically know the value of ...
(Date:5/19/2013)... The report “Feed Additives Market by ... up to 2017” published by MarketsandMarkets, defines and segments ... forecasting of the global volume and revenue for the ... restraining factors for the global market with analysis of ... market is segmented and revenue is forecasted on the ...
(Date:5/19/2013)... Dr. Keith Chertok now provides gum disease patients with ... increase the chance of a healthier smile. Laser gum ... not only removes diseased gum tissue in patients, but it ... dental implants. , LANAP uses a laser to ... help stimulate the healthy tissue as well as encourage new ...
(Date:5/19/2013)... Exciting new Skin Brushes are available from ... practice known through the ages but is a lost ... brushing, has so many benefits for our health and ... love that circulation and lymphatic systems get a boost ... is supported through Skin Brushing." , Why is Skin ...
(Date:5/19/2013)... Vedra Beach, Florida (PRWEB) May 19, 2013 ... value and market access, is pleased to unveil a ... trade show environment that provides a powerful array of ... to partners in the US and abroad. , HE-Xpo ... and will offer attendees the look and feel of ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 3Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 2Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 3Health News:Berkeley, CA Periodontist, Dr. Keith Chertok Now Treats Gum Disease Patients With Laser Gum Surgery Prior to Placing Dental Implants 2Health News:Exciting New Skin Brushes at Sublime Beauty® Bring Health and Beauty Benefits; Celebrities and Models Know the Secret 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 3
... Institute scientists, discovery of a cancer-causing gene the first ... how the panoramic view of genomics and the close-up perspective ... involved in cancer and which are mere bystanders. The findings ... Nature . "In the coming years, we can ...
... , ROCHESTER, Minn., June 24 The Mayo Clinic ... collaborative symposium on innovations in health care experience and ... open to the public. It will feature nationally recognized ... in health care delivery models, including Web-based tools. The ...
... finds , WEDNESDAY, June 24 (HealthDay News) -- Monitoring ... drugs to prevent osteoporosis is unnecessary and could be ... researchers analyzed data from a large randomized trial that ... used bisphosphonate) in more than 6,000 postmenopausal women with ...
... Furthering its mission to improve the quality of ... signed a cooperative agreement with nine countries belonging ... In a drive to strengthen capacities and certification ... from Cambodia, Laos, Myanmar, Singapore, Vietnam, Indonesia, Malaysia, ...
... ... Services , ... Francisco, CA (PRWEB) June 24, 2009 -- Today, Quantros announced the launch of a ... Quantros IT Consulting Services provides a cost-effective and reliable model for creating and supporting ...
... "Superfruit" Beverages Expand Beverages Holdings, Wholesome Offerings , , ... of the Sunny Delight Beverages Co., Veryfine Co. and The ... all the assets of Bossa Nova Beverage Group, Inc., a ... beverage category with its original acai juice . ...
Cached Medicine News:Health News:Study pinpoints novel cancer gene and biomarker 2Health News:Study pinpoints novel cancer gene and biomarker 3Health News:Study pinpoints novel cancer gene and biomarker 4Health News:Mayo Clinic Center for Innovation to Sponsor a Collaborative Symposium on Innovations in Health Care Experience and Delivery 2Health News:Mayo Clinic Center for Innovation to Sponsor a Collaborative Symposium on Innovations in Health Care Experience and Delivery 3Health News:Bone Therapy May Not Always Need Monitoring 2Health News:Goal of good quality medicines advanced by new USP agreement with 9 ASEAN countries 2Health News:Quantros Establishes IT Consulting Services Business Unit 2Health News:Quantros Establishes IT Consulting Services Business Unit 3Health News:Beverages Holdings, LLC Acquires Bossa Nova: The Superfruit Company 2Health News:Beverages Holdings, LLC Acquires Bossa Nova: The Superfruit Company 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: